Kira Biotech

Kira Biotech is an emerging Australian biotechnology company developing novel immune-modulating compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class selective immune cell depleting monoclonal antibody targeting activated immune cells, designed to restore balance by inducing immune tolerance. Kira Biotech has attracted venture capital funding and is advancing KB312 through preclinical development and Phase I clinical trials, led by a team of drug development experts headed by renowned U.S. rheumatologist and immunologist Dr. Dan Baker.